TQB2618
As of the edition of 20 October 2026, TQB2618 is a drug known only by a code name: stopped in 2025; acts on HAVCR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Code name only
- Registered trials
- 5, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of TQB2618.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HAVCR2 | Hepatitis A virus cellular receptor 2 | Q8TDQ0 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 0 | 0 | 1 |
| Phase 2 | 1 | 0 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2020 to now |